Core Viewpoint - 九州通's subsidiary received approval for the listing application of Betahistine Dihydrochloride Tablets, which are used for Meniere's disease and cerebral vascular diseases, indicating potential growth in product offerings to meet aging population needs [1] Recent Events - 九州通 announced that its controlling shareholder, Chuchang Investment, has prematurely released the pledge of 11.3 million shares (2.46% of its holdings), while a related party, Shanghai Hongkang, pledged 11.7 million shares (1.08% of its holdings). As of the announcement date, the total pledged shares by Chuchang Investment accounted for 57.29% of its holdings and 26.03% of the company's total share capital [2] - The company is positioned as a digital service provider in the AI medical ecosystem, supporting the Ant Group's supply chain, with over 50 million orders in 2025, reflecting a 180% year-on-year increase [2] Stock Performance - As of February 12, 2026, 九州通's stock price was 5.21 yuan, with a cumulative decline of 1.14% over the past five days and a price fluctuation of 2.66%. The net outflow of main funds was 11.51 million yuan, with a turnover rate of 0.23%. The technical analysis indicates the stock is in a consolidation phase, with a 20-day moving average of 5.31 yuan, a Bollinger Band resistance level of 5.56 yuan, and a support level of 5.08 yuan [3] Institutional Viewpoints - The market is focusing on the integration of AI medical technology and pharmaceutical distribution digitalization. 九州通 is enhancing supply chain efficiency through smart warehousing and blockchain technology, with its pharmaceutical industrial business generating 2.3 billion yuan in revenue in the first three quarters of 2025, a year-on-year increase of 9.93%. However, there is uncertainty regarding the approval results for the newly accepted drugs [4]

Market Overview - On February 12, 2026, the A-share market showed mixed results, with the Shanghai Composite Index closing at 4131.98 points, up 0.09%, while the Shenzhen Component Index fell 0.35% to 14160.93 points, and the ChiNext Index dropped 1.08% to 3284.74 points. Over 3200 stocks declined, and the total trading volume in the Shanghai and Shenzhen markets was 1.98 trillion yuan, a decrease of 120 billion yuan from the previous trading day [1]. - The Hong Kong stock market saw all three major indices rise, with the Hang Seng Index increasing by 0.31% or 83.23 points to close at 27266.38 points, and a total trading volume of 217.22 billion HKD. The Hang Seng China Enterprises Index rose by 0.28% to 9268.18 points, while the Hang Seng Tech Index gained 0.9% to 5499.99 points [1]. - In the U.S. stock market, all three major indices closed lower, with the Dow Jones Industrial Average down 0.13% to 50,121.40 points, the S&P 500 slightly down by 0.34 points to 6,941.47 points, and the Nasdaq Composite Index falling 0.16% to 23,066.47 points [1]. Important News - The State-owned Assets Supervision and Administration Commission (SASAC) has urged central enterprises to enhance investment in computing power and promote the synergy between "computing power and electricity." This initiative aims to improve data governance capabilities and strengthen the foundation of the artificial intelligence industry [1]. - During a recent meeting, SASAC emphasized the need for central enterprises to focus on independent innovation, particularly in overcoming key core technologies and advancing "large model" technologies. The goal is to transform more independent innovation results from prototypes into products and establish industries [1]. - SASAC also called for the cultivation of application scenarios, ensuring precise alignment between artificial intelligence and core business needs, with a focus on high adaptability, high value, and high reliability [1]. - Additionally, SASAC highlighted the importance of open-source collaboration, urging central enterprises to accelerate the iteration and upgrade of open-source "renewal communities" and strive to become "empowering enterprises," thereby fostering the construction of an "AI+" industrial community and nurturing a mutually beneficial industrial ecosystem [1].

每经头条（nbdtoutiao）——男子街头逃亡、剑客山间打斗……电影级中国视频大模型被称"地表最 强"，几十个提示字生成15秒视频可商业交付，影视股大涨！记者亲测 （记者 张明双） 每经AI快讯，广济药业2月11日晚间发布公告称，本次向特定对象发行股票相关事项已经公司第十一届 董事会第十五次（临时）会议审议通过。本次向特定对象发行股票的发行对象为公司控股股东长江产业 集团，发行对象符合法律、法规的规定。本次向特定对象发行股票数量按照募集资金总额除以最终发行 价格计算得出，数量不足1股的余数作舍去处理，即发行数量不超过约9494万股（含本数），不超过本 次发行前公司总股本的30%。发行价格为6.32元/股。本次发行拟募集不超过6亿元，扣除发行费用后， 用于偿还借款和补充流动资金。 ...

Core Viewpoint - Dong'e Ejiao plans to invest 1.485 billion yuan in a health consumer goods industrial park, marking one of its largest single investments in recent years [1][3] Group 1: Investment Details - The investment includes 1.421 billion yuan for fixed assets and 64 million yuan for liquidity support [1] - The project will cover an area of 406,800 square meters with a construction area of approximately 151,100 square meters, and is expected to take 22 months to complete [3] - This investment aligns with the company's "1238" strategy, which aims to develop a dual-driven growth model of pharmaceuticals and health consumer goods [3] Group 2: Business Strategy - The health consumer goods sector is characterized by diverse demand and rapid product iteration, necessitating higher standards for R&D, quality, and agile supply chains [3] - The existing industrial park faces limitations in expansion and capacity bottlenecks, prompting the need for new facilities to meet the fast-paced development of health consumer goods [3] - The new investment is seen as a strategic move to capitalize on the growing health industry and the trend of "younger health consumption" [3] Group 3: Financial Implications - The investment will consume a significant portion of the company's cash reserves, which stood at approximately 8.2 billion yuan as of the end of Q3 last year [6] - The shift towards heavier asset allocation may lead to a decline in fixed asset turnover during the construction phase, potentially impacting short-term profitability [6] - As of February 11, the company's stock price was 55.44 yuan, with a market capitalization of 35.7 billion yuan, reflecting an 18% decline over the previous year [6] Group 4: Market Competition - Investors express mixed opinions on the investment, with concerns about the impact on the company's balance sheet and liquidity [4] - Competitors in the health consumer goods space include Kunming Pharmaceutical, Yunnan Baiyao, and others, which may pose challenges for Dong'e Ejiao in achieving expected performance [7]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has released a list of key tasks for the healthcare sector for 2026, emphasizing the opening of cross-province mutual aid for employee medical insurance personal accounts across all provinces [1][3]. Group 1: Cross-Province Mutual Aid - All provinces will open cross-province mutual aid for employee medical insurance personal accounts, allowing funds to cover medical expenses for the insured's close relatives [1][3]. - As of early January 2026, 337 coordinated areas have launched healthcare wallets to facilitate cross-province mutual aid [1][3]. Group 2: Key Tasks for 2026 - By the end of 2026, 80% of designated medical institutions nationwide are expected to achieve instant settlement [4][6]. - At least one batch of national organized drug and high-value medical consumables centralized procurement will be conducted [4][6]. - The direct settlement of maternity medical expenses for inpatient childbirth across coordinated areas within the province will be basically realized [4][6]. Group 3: Additional Services - Maternity allowances will be directly issued to individuals without needing to go through employers, enhancing the efficiency and satisfaction of insured individuals [2][6]. - Key hospitals will enable cross-province retrieval of medical imaging under the healthcare insurance system, with at least 45% of imaging indexes uploaded to the national healthcare information platform by the end of 2026 [3][7].

欢迎扫描下方二维码关注： 脚本： 靳清阳 制 作：周鼎承 来源北京税务 来源： 北京税务 准予在以后纳税年度结转扣除。 我逛街的时候，看见好多化妆品 新年大促销，在各大商场投放了 广告，他们的广告费税前扣除标 准和我们一样吗? 不一样！ 广告费的扣除 比例不是唯一的哦 ~ 知识点: 自2026年1月1日起至2027年12月 31日，对化妆品制造或销售、医药制造和 饮料制造（不含酒类制造）企业发生的广 告费和业务宣传费支出,不超过当年销售 (营业）收入30%的部分,准予扣除;超 过部分，准予在以后纳税年度结转扣除。 这里还要特别提一下烟草企 业，烟草广告费和业务宣传 费支出，一律不得在计算应 纳税所得额时扣除。 我明白了，广告费不是花 多少扣多少，一般企业和 特定行业企业的扣除比例 是的。 也是不一样的。 政策依据: 1.《中华人民共和国企业所得税法实 欢迎扫描下方二维码关注： 温馨提醒：蓝色柳林财税室为非官方平台，是由编者以学习笔记形式建立的平台，所有笔记写作记录的文章及转发的法律法规仅供读者学习 参考之用，并非实际办税费的标准，欢迎交流学习，共同分享学习经验成果。文章版权归原作者所有，如有不妥，请联系删除。 ...

Market Performance - The Dow Jones Industrial Average reached a new all-time high, peaking at 50,512.79 points during the day, closing with a slight gain of 0.1% [2] - The Nasdaq and S&P 500 indices turned negative, with declines of 0.59% and 0.33% respectively [2] - Large-cap tech stocks showed mixed results, with Tesla rising nearly 2%, while major players like Microsoft, Apple, Nvidia, Amazon, and Meta experienced declines [4][5] Chinese Stocks - The Nasdaq Golden Dragon China Index saw a continuous rise for four trading days, increasing by nearly 1% [5] - Notable Chinese stocks such as Shengda Technology and Dingdong Maicai surged over 7%, while Hesai Technology and Zai Ding Pharmaceutical rose over 6% [5][6] Precious Metals - International gold prices fluctuated around $5,000 per ounce, while silver prices hovered near $80 per ounce [8] - As of February 11, gold futures and spot prices fell by 0.6% and 0.71%, respectively, while silver futures and spot prices dropped over 2% and 3% [8] - Analysts suggest that while gold remains at high levels, silver still has relative upside potential, although caution is advised due to high volatility [10] Oil Market - International oil prices experienced slight declines, with NYMEX crude futures and ICE Brent futures reported at $64.19 per barrel and $69.01 per barrel, respectively [8]

证券日报网讯 2月10日，欧康医药发布公告称，公司2025年实现营业收入334250823.12元，同比增长 7.73%；归属于上市公司股东的净利润11623260.91元，同比下降48.21%。 （文章来源：证券日报） ...

Group 1 - The article discusses the unconditional approval of several business concentration cases by the market regulatory authority [2][3] - The approved cases include acquisitions by Wuhan Urban Construction Group Co., Ltd. of Hubei Water Resources and Hydropower Construction Co., Ltd., and Jiang Pharmaceutical Group Co., Ltd. of Henan Tailong Pharmaceutical Co., Ltd. [3] - Other notable approvals include FountainVest Capital Partners GP4 Ltd.'s acquisition of Jixiangju Food Co., Ltd. [3]

截至2026年2月10日 13:20，中证医药及医疗器械创新指数(931484)上涨0.57%，成分股惠泰医疗上涨 4.86%，海思科上涨3.61%，康龙化成上涨2.55%，药明康德上涨2.31%，恩华药业上涨1.89%。医疗创新 ETF(516820)上涨0.55%，最新价报0.37元。 消息面上，2月9日，1-8批国家集采药品新一轮接续采购开标产生拟中选结果。本次接续采购涉及1-8批 国家集采的316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系统、 消化系统等26个治疗领域。全国5.1万家医药机构参加报量，共1091家国内外企业的4623个产品参与投 标，1020家企业的4163个产品获得拟中选资格。 东海证券指出，小核酸赛道的高景气度持续延续，从罕见病向慢病领域加速渗透，市场规模持续扩容； 跨国药企布局意愿提升，国内本土企业技术获国际认可，出海路径清晰，供应链优势凸显，板块投资价 值持续提升。后续投资建议聚焦三大核心主线：一是具备核心递送技术、拥有国际合作潜力的新锐 biotech；二是布局慢病领域（心血管、代谢等）、管线进度领先、可复制Leqvio商业化路径的行业龙 头；三 ...